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Cowden syndrome (CS), a Mendelian autosomal-dominant disorder, predisposes to breast, thyroid and other
cancers. Germline mutations in phosphatase and tensin homolog (PTEN) have been recently reported in 23%
ofa largeseries ofclassicCS.Here, wevalidated oursmall (n 5 10)pilotstudyinalargepatientseriesthatgerm-
linevariationsinsuccinatedehydrogenasegenes(SDHx)occurin8%(49/608)ofPTENmutation-negativeCSand
CS-like (CSL) individuals (SDH
var1). None of these SDHx variants was found in 700 population controls (P <
0.0001). We then found that SDHx variants also occur in 6% (26/444) of PTEN mutation-positive (PTEN
mut1)
CS/CSL individuals (PTEN
mut1/SDH
var1). Of 22 PTEN
mut1/SDH
var1 females, 17 had breast cancers compared
with 34/105 PTEN
mut1 (P < 0.001) or 27/47 SDH
var1 patients (P 5 0.06). Notably, individuals with SDH
var1 alone
had the highest thyroid cancer prevalence (24/47) compared with PTEN
mut1 patients (27/105, P 5 0.002) or
PTEN
mut1/SDH
var1 carriers (6/22, P 5 0.038). Patient-derived SDH
var1 lymphoblastoid cells had elevated cellular
reactiveoxygenspecies,highestinPTEN
mut1/SDH
var1cells,correlatingwithapoptosisresistance.SDH
var1cells
showed stabilized and hyperactivated hypoxia inducible factor (HIF)1a signaling. Most interestingly, we also
observed the loss of steady-state p53 in the majority of SDH
var1 cells. This loss of p53 was regulated by
MDM2-independent NADH quinone oxidoreductase 1-mediated protein degradation, likely due to the imbalance
ofﬂavinadeninedinucleotide/nicotinamideadeninedinucleotideinSDH
var1cells.Ourdatasuggestthepotential
regulation of HIF1a, p53 and PTEN signaling by mitochondrial metabolism in CS/CSL tumorigenesis. Together,
our ﬁndings suggest the importance of considering SDHxas candidate predisposing and modiﬁer genes for CS/
CSL-related malignancy risks, and a mechanism which suggests ways of therapeutic reversal or prevention.
INTRODUCTION
Cowden syndrome (CS, [MIM 158350]) is autosomal dominant
with lifetime risks of 28% for developing female breast cancer,
10% for epithelial thyroid cancer and unknown but ﬁnite risks
of developing other cancers (1,2). The syndrome is difﬁcult to
recognize because of the protean and variable manifestations of
the broad phenotype (2) and remains under-diagnosed. The
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Advance Access published on October 6, 2011incidence of CS was estimated tobe 1 inone million (3,4)b e f o r e
geneidentiﬁcationandraisedto1in200 000after(5),whichmay
still be an underestimate. Germline mutations in the phosphatase
and tensin homolog deleted on chromosome 10 (PTEN [MIM
601728]) tumor suppressor gene were found in up to 85% of
CS cases deﬁned by the strict International Cowden Consortium
criteria (6), although in a recent series comprising .3000 pro-
bands, only 23% of classic CS carry a germline PTEN mutation
(7).Thistrendinmutationprevalencewithtimefrominitialgene
discovery is typical for many heritable syndromes as more pro-
bands without family histories and without full phenotype are
analyzed, thus making molecular diagnosis difﬁcult and predict-
ive testing challenging, often impossible. When individuals have
features of CS but do not meet these criteria, they are referred to
as CS-like (CSL) and necessarily represent a heterogeneous
series. Only 5% of CSL individuals have germline PTEN muta-
tions (8). Thus, illustrative of many cancer syndromes and rele-
vant to clinical practice, other predisposition genes must exist
for PTEN mutation-negative CS/CSL individuals and families.
Recently, mitochondrial respiratory enzymes have emerged
as tumor suppressors, including autosomal genes encoding
mitochondrial complex II–succinate dehydrogenase (SDH)
(reviewed in 9). Germline homozygous or compound hetero-
zygous mutations in mitochondrial complex genes, including
complex II, result in Leigh syndrome, a rare but fatal neurode-
generative disease. Germline heterozygous SDHB/C/D muta-
tions result in hereditary pheochromocytoma–paraganglioma
(PCC/PGL) syndrome (10–12). We subsequently noticed a
small subset of individuals with germline SDHB mutations
in our population-based PCC registry also developed early
onset renal cell carcinoma (RCC) and papillary thyroid carcin-
oma, reminiscent of two CS component tumors (12,13). Based
on these observations, we carried out a small hypothesis-
generating pilot study, which found germline SDHB and
SDHD variants in a subset of CS/CSL individuals without
PTEN mutations (14). Based on small numbers (n ¼ 10), it
appeared that germline SDHx variant carriers may have ele-
vated frequencies of breast, thyroid and RCC compared with
those with germline PTEN mutations. It also appeared that
the SDH-related thyroid cancers were papillary in contrast to
PTEN-related thyroid cancers whereby follicular histology is
over-represented. However, the sample size was small. Func-
tionally, CS/CSL-associated SDHB or SDHD variants showed
similar activation of AKT (protein kinase B) and mitogen-acti-
vated protein kinase (MAPK) signaling, which are down-
stream of the PTEN pathway in a variant-dependent manner,
indicating the likely cross-talk between the SDH and PTEN
signaling pathways (14).
In the present study, we sought to address our hypotheses
that germline SDHx variants associate with increased frequen-
cies of component cancers in a large independent series of
PTEN mutation-negative CS/CSL individuals; and that SDHx
alleles modify solid tumor risks in individuals with germline
PTEN mutations. Because the SDHx alleles are missense var-
iants, it was important to demonstrate functional relevance.
So, we then explored mechanisms whereby SDHx variants
can lead to tumorigenesis by examining cellular phenotypes
such as apoptosis and reactive oxygen species (ROS) status,
and candidate dysregulated signaling pathways.
RESULTS
SDHB/D germline variants identiﬁed in PTEN
mutation-negative and PTEN mutation-positive
CS/CSL patients
Manganese superoxide dismutase (MnSOD) is an indicator
of ROS stress and of general mitochondrial dysfunction.
Following a similar workﬂow (Supplementary Material,
Fig. S1) as in our pilot paper (14), PTEN mutation-negative
CS/CSL germline samples with elevated MnSOD levels
(n ¼ 608, including 10 pediatric patients; Supplementary
Material, Table S2) were subjected to SDHB/C/D mutation
analysis and their data compared with ancestry-matched
controls (n ¼ 700). We found 49 of 608 (8%) PTEN
mutation-negative cases carrying non-synonymous germline
SDHx mutations/variants (Table 1, upper panel): 17 in
SDHB [Ala3Gly (n ¼ 1), Arg27Gly (n ¼ 1), His57Arg
(n ¼ 1), Asn120Ser (n ¼ 1) and Ser163Pro (n ¼ 13)], 1 in
SDHC [Ala66Val] and 31 in SDHD [Gly12Ser (n ¼ 18),
His50Arg (n ¼ 12), His145Asn (n ¼ 1)]. None of these
SDHx variants was found in the 700 population controls
(P , 0.0001).
In order to determine whether SDHx variation and PTEN
mutation are mutually exclusive or can occur together, we
examined a nested series of 444 PTEN mutation-positive
CS/CSL patients (Supplementary Material, Table S2) with
germline PTEN mutation/variant, including promoter
variants and large insertions/deletions, regardless of the
MnSOD status. Of the 444, 26 (6%) were also found to
carry germline SDHB/D variants, 12 in SDHB [Ala3Gly
(n ¼ 1), Gly53Glu (n ¼ 1), Ser163Pro (n ¼ 9), Ala215Thr
(n ¼ 1)] and 14 in SDHD [Gly12Ser (n ¼ 3), His50Arg
(n ¼ 11)] (Table 1, lower panel).
Table 1. List of SDHx variants identiﬁed in CS/CSL individuals in PTEN
mutation-negative subset and PTEN mutation-positive subset
Variation n
PTEN mutation-negative subset: (8%, 49/608)
SDHB (n ¼ 17) c.8C.G, p.Ala3Gly 1
c.9C.G, p.Arg27Gly 1
c.170A.G, p.His57Arg 1
c.359A.G, p.Asn120Ser 1
c.487T.C, p.Ser163Pro 13
SDHC (n ¼ 1) c.197C.T, p.Ala66Val 1
SDHD (n ¼ 31) c.34G.A, p.Gly12Ser 18
c.149A.G, p.His50Arg 12
c.433C.A, p.His145Asn 1
PTEN mutation-positive subset: (6%, 26/444)
SDHB (n ¼ 12) c.8C.G, p.Ala3Gly 1
c.158G.A, p.Gly53Glu 1
c.487T.C, p.Ser163Pro 9
c.643G.A, p.Ala215Thr 1
SDHD (N ¼ 14) c.34G.A, p.Gly12Ser 3
c.149A.G, p.His50Arg 11
SDHB RefSeq NM_003000.2.
SDHC RefSeq NM_003001.3.
SDHD RefSeq NM_003002.1.
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in SDHx variant carriers in PTEN mutation-negative
CS/CSL individuals
The snapshot prevalence of breast, epithelial thyroid and RCC
were calculated for the 47 adult individuals carrying SDHx
variants only (i.e. without PTEN mutations). Of the 47 patients
with SDHx variants, 27 (57.4%) had breast cancer, 24 (51.1%)
had epithelial thyroid cancers and 3 (6.4%) RCC (Table 2,
upper panel). When compared with patients with only PTEN
mutations, SDHx variant carriers showed odds ratios (OR) of
2.82 (95% CI 1.39–5.72, P ¼ 0.001) for breast cancer, and
3.01 (1.47–6.19, P ¼ 0.002) for epithelial thyroid carcinoma
(Table 2). The prevalence of RCC in SDHx variant carriers
is similar to PTEN mutations carriers. Epithelial thyroid
cancers seen in the SDHx variant carriers were mostly papil-
lary (22/24, 91%) in histology (majority classic papillary)
compared with only one-third among pathogenic PTEN
mutation carriers (P , 0.001).
SDHx alleles associated with modiﬁed malignancy risks
in PTEN mutation carriers
Strikingly, breast cancers developed in 77% (15) of 22 patients
carrying both PTEN mutations and SDHx variants (11 invasive
ductal carcinomas and 6 ductal carcinoma in situ) when
compared with patients with PTEN mutations alone (32.4%)
[P , 0.001; OR ¼ 7.10 (95% CI: 2.41–20.86)], or compared
with patients with SDHx variants alone (57.4%) [P ¼ 0.06,
OR ¼ 2.52, (95% CI: 0.80–7.98)]. There were 6 of 22
(27.2%) carriers of both PTEN mutation and SDHx variant
with thyroid cancer compared with 27 of 105 (25.7%) in
those with PTEN mutations alone [P ¼ 0.21, OR ¼ 1.08
(95% CI: 0.39–3.05)] in contrast to 24 of 47 (51.1%) with
SDHx variants alone [P ¼ 0.038, OR ¼ 0.34 (95% CI: 0.12–
1.08)]. While the prevalence of thyroid cancer in patients
with both PTEN mutations and SDHx variants is not statistic-
ally signiﬁcantly different from that of PTEN mutation-only
patients, the histology of these 6 PTEN/SDHx-related thyroid
cancers was exclusively papillary. No RCC were noted in
the group with both PTEN mutation and SDHx variant.
Enhanced apoptosis resistance correlated with elevated
ROS in SDHx variant carriers
Based on our genotype–phenotype observations above, we
hypothesized that the functional consequences of the
co-occurrence of PTEN and SDHx alterations would be more
marked, beyond those of SDHx alteration alone. To evaluate
if SDHx variants have any effect in regulating cell death,
patient-derived lymphoblastoid cells from controls, SDHx
variant carriers (SDH
var+) and individual samples that have
both SDHx variant and PTEN mutation (SDH
var+/PTEN
mut+)
were serum starved overnight and allowed to grow under
low serum [0.2% fetal bovine serum (FBS)] conditions for
36 h before measuring the percentage of cells in the sub-G1
cell cycle phase by ﬂow cytometry (Fig. 1A). This revealed
a pattern of additive cell death resistance with SDHx variants
in the presence of PTEN mutations. Although some apoptosis
resistance was seen in cells with only SDHx variants, it was
not as pronounced as those with both PTEN mutation and
SDHx variant. ROS marker microscopy revealed signiﬁcantly
increased intracellular ROS levels in representative samples
harboring SDHx variants compared with normal controls
(Fig. 1B), with or without PTEN mutation, consistent with
our previous ﬁnding (14). Quantitative ﬂow cytometry experi-
ments using the same carboxy-H2DCFDA live cell labeling
conﬁrmed this observation (Fig. 1C). Interestingly, samples
with both PTEN mutations and SDHx variants showed
higher ROS compared with samples with SDHx variants
alone. Moreover, these observations are inversely correlated
with the degree of cell death (Fig. 1A).
Hypoxia inducible factor (HIF)1a stabilized in samples
from SDHx variant carriers
In SDH-related PCC/PGL syndromes, pseudohypoxia-induced
stabilization of hypoxia inducible factor (HIF)1a was
hypothesized (16). In order to investigate if the pseudo-
hypoxia hypothesis is also applicable to CS/CSL in the
context of PTEN and SDH cross-talk, we analyzed HIF1a
protein expression levels in PTEN or SDHx mutation/variant
carriers when compared with normal control samples. SDHx
variant-positive samples showed increased levels of HIF1a
protein compared with controls (Fig. 2A). This result was
Table 2. Increased cancer frequencies in SDHx variant-only carriers and in PTEN mutationand SDHx variant double-carriers compared with PTEN mutation-only
carriers
Breast cancer (/total number) Thyroid cancer (/total number) Renal cancer (/total number)
PTEN
mt+ 34/105 (32.4%) 27/105 (25.7%) 7/105 (6.7%)
SDHx
var+ 27/47 (57.4%) 24/47 (51.1%) 3/47 (6.4%)
PTEN
mt+/SDHx
var+ 17/22 (77.2%) 6/22 (27.3%) 0
SDHx
var+ versus PTEN
mt+ P-value 0.001 0.002 0.28
OR (95% CI) 2.82 (1.39–5.72) 3.01 (1.47–6.19) 0.95 (0.24–3.87)
PTEN
mt+/SDHx
var+ versus SDHx
var+ P-value 0.06 0.038
OR (95% CI) 2.52 (0.80–7.98) 0.34 (0.12–1.08)
PTEN
mt+/SDHx
var+ versus PTEN
mt+ P-value ,0.001 0.21
OR (95% CI) 7.10 (2.41–20.86) 1.08 (0.39–3.05)
P-values derived from Fisher’s two-tailed exact test. P-value ,0.05 is considered statistically signiﬁcant and is in italics. OR, odds ratio; CI, conﬁdent interval.
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mutation-positive patients showed reduced PTEN protein,
while HIF1a protein levels were no different from those of
wild-type controls (Fig. 2A). SDHx variant-positive samples
showed a lower HIF1A transcriptional expression relative to
samples with PTEN mutations (Fig. 2C). In contrast to the
protein expression, interestingly, truncating PTEN mutations
was associated with moderately decreased HIF1A transcript
and virtually no HIF1a protein. As a conﬁrmation of enhanced
HIF1a transactivity due to protein stabilization, one of the
well-known HIF1a target genes, vascular endothelial growth
factor (VEGF) transcriptional expression was examined
using quantitative reverse-transcription polymerase chain
reaction (RT–PCR). As shown in Figure 2D, relative VEGF
mRNA expression was signiﬁcantly increased in SDHx
variant carriers compared with normal controls.
Enhanced baseline p53 ubiquitin-independent degradation
in SDHx variant-positive cells
Exposure of cells to high levels of ROS leads to oxidative
stress, and should induce a p53-mediated response including
apoptosis, whereas we observed the opposite in our cases.
Therefore, we decided to investigate if p53 is somehow modi-
ﬁed in our patient samples in order to escape the expected
apoptotic regulation. Western blots showed reduced p53
protein expression in the majority of samples harboring
SDHx variants compared with normal controls (Fig. 3A and
B, upper panels). In contrast to p53 protein levels, TP53
mRNA expression was not changed in SDHx variant-positive
samples compared with controls (Fig. 3C), suggesting that
the loss of p53 protein was not from down-regulated TP53
transcript. Cells treated with proteasome inhibitor MG132
Figure 1. Cellular phenotypes observed in patient cells. (A) Cell death is reduced in cells carrying only SDH variants (SDH
var+) and in samples with both PTEN
mutation and SDH variant (SDH
var+/PTEN
mut+). Note the slight reduction in SDH
var+ cells in sub-G1 phase compared with control cells and signiﬁcant reduc-
tion in sub-G1 cells from SDH
var+/PTEN
mut+ patients compared with controls (Mean + SEM). (B) Increased intracellular ROS in samples with SDHx variants.
Representative ﬂuorescent microscopic images with carboxy-H2DCFDA ROS labeling (green) and Hoechst 33342 nuclear labeling (blue). The non-ﬂuorescent
5-(and-6)-carboxy-2′,7′-dichlorodihydroﬂuorescein diacetate permeates live cells and is deacetylated by non-speciﬁc intracellular esterases. In the presence of
non-speciﬁc ROS, reduced ﬂuorescein compound is oxidized and emits bright green ﬂuorescence. Green dots in ﬁgures represent cells with higher cellular ROS.
(Upper panel) Four normal control samples (193xx, 202xx, 203xx, 198xx) and one positive control sample treated with ROS inducer tert-butyl hydroperoxide
(TBHP). (Lower panel) Four CS/CSL patient samples with SDHx variants (patient ID—SDHx variant: 829LL-S163P, 1902BS-S163P, 1617LS-G12S,
2369JB-S163P) and one PGL patient sample with SDHB truncation mutation R46X (3475MG). (C) Quantitative ROS measurement by ﬂow cytometry labeling
with carboxy-H2DCFDA in normal control, SDH
var+, and SDH
var+/PTEN
mut+ groups (mean + SEM).
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variant-positive cells (Fig. 3A and B, lower panels), indicating
that the loss of p53 protein is most likely due to enhanced
protein degradation. The multiple bands .53 kDa are likely
ubiquitinated p53 resulting from proteasomal inhibition.
To further explore the regulation of p53 degradation, we
then investigated the main MDM2-related proteasomal deg-
radation pathway (15,17). No corresponding increase in
MDM2 or p-MDM2 was observed (Supplementary Material,
Fig. S2A). Because NADH quinone oxidoreductase 1
(NQO1) has been shown to bind and stabilize p53 through
MDM-independent pathways (18–20), we next checked the
NQO1 status in our control and patient cell lines with the hy-
pothesis that either absolute levels of NQO1 could be reduced
or the interaction between NQO1 and p53 could be disrupted
in the presence of SDHx variation. First, we did not observe
obvious decreases of NQO1 expression (Supplementary
Material, Fig. S2B) in SDHx variant-positive cells, indicating
that decreased p53 protein was not a consequence of decreased
NQO1 expression. Secondly, dose-dependent induction of
NQO1 by NQO1 inducer dimethyl fumarate (DMF) treatment
had no signiﬁcant impact on either p53 protein expression or
cell apoptosis in SDHx variant-positive cells either (Supple-
mentary Material, Figs S2C and S2D), indicating that NQO1
induction cannot rescue the SDHx variant-associated loss of
p53. Finally and importantly, co-immunoprecipitation experi-
ments showed decreased binding between NQO1 and p53 in
SDHx variant-positive patient cells compared with controls
(Fig. 3D), suggesting that the loss of p53 is indeed caused
by defective interactions between NQO1 and p53.
Altered ﬂavin adenine dinucleotide (FAD) and
nicotinamide adenine dinucleotide (NAD) concentrations
in SDHx variant carrier samples
We then hypothesized that the impaired binding between
NQO1 and p53 may be caused by accumulated ﬂavin
adenine dinucleotide (FAD), which is a cofactor for both
NQO1 and SDH enzymatic activity. To test this hypothesis,
FAD and nicotinamide adenine dinucleotide (NAD)+/
Figure 2. HIF1a protein stabilized with accumulation in SDHx variant-positive samples. (A) Western blot analysis of HIF1a, PTEN and b-actin protein expres-
sion in PTEN mutation-positive, SDHx variant-positive patients including (patient ID—SDHx variant): 826GV-H50R, 1617LS-G12S, 1902BS-S163P,
2369JB-S163P, positive controls (Pos Ctr, samples stimulated with CoCl2 to mimic hypoxia condition) and normal (Neg Ctr) controls. Relative levels of
HIF1a protein were quantitated by densitometry and normalized to b-actin in right panel. Results are fold change in SDH
var+ carriers compared with
normal control cells. (B) A dot blot analysis of HIF1a protein expression in SDH
var+ samples and controls. Relative levels of HIF1a protein were quantitated
by densitometry in right panel. Results are fold change in SDH
var+ carriers compared with normal control cells. (C) Relative HIF1a mRNA expressions in PTEN
mutation-positive and SDHx variant-positive patients compared with normal controls. (D) Relative VEGF mRNA expression is upregulated in SDHx variant-
positive samples. Data were presented as (Mean + SEM). ∗P , 0.05.
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measured directly in control and SDHx variant carrier lympho-
blastoid cells. Indeed, we observed elevated FAD level in
SDHx variant-positive cells compared with controls
(Fig. 4A, left panel). In contrast to higher FAD levels,
NAD+ was lower in SDHx variant-positive cells with no
change in NADH (Fig. 4A, middle and right panels). When
we supplemented normal control cells with an excess
(250 mM) of riboﬂavin (FAD precursor) for 48 h, signiﬁcant
reductions in NAD+ levels (Fig. 4B) were also detected,
but not NADH, and were accompanied by increased cellular
FAD. This is consistent with our observations in SDHx
variant-positive patient cells. More interestingly, FAD-treated
control cells showed similar reductions in p53 expression
(Fig. 4C), mirroring our observations in non-FAD-treated
patients cells carrying SDHx variants (above). FAD treatment
of control cells resulted in increased p-AKT and p-MAPK
activation, mimicking the inactivation of the PTEN pathway,
without changing PTEN protein expression.
DISCUSSION
Individuals with heritable cancer syndromes, such as CS/CSL,
who do not carry mutations in the known predisposition
genes, bring challenges to molecular diagnosis, predictive
testing of family members, genetic counseling and preventive
medicalmanagement.Identifyingadditionalcancersusceptibil-
ity genes for CS/CSL would improve and facilitate the gene-
speciﬁcpersonalizedmedicalcare.Wehaverecentlyuncovered
an alternative mechanism, germline hypermethylation of the
tumor suppressor gene KLLN (encoding KILLIN), accounting
for one-third of PTEN mutation-negative CS/CSL (21). Germ-
line KLLN hypermethylation is associated with increased risks
of breast and renal cancers over those with PTEN mutations.
Our current study not only validates the previous pilot observa-
tions that SDHx variants occur in  8% of PTEN mutation-
negative CS/CSL patients, but also validates the elevated
breast and thyroid cancer frequencies over those with PTEN
mutations. SDHx, together with PTEN and KLLN, may form a
panel of predisposition genes considered for genetic testing
for CS/CSL, perhaps prioritized based on the individual
patient’s clinical phenotype at presentation and their family
history. For example, if a CS/CSL individual has papillary
thyroidcarcinoma,thenSDHxtestingshouldbeconsideredﬁrst.
As with all inherited cancer syndromes to date, while we
can counsel increased prevalence of speciﬁc cancers, we
cannot predict which subset of those with PTEN mutations
will develop each component cancer. Here we have found
that 6% of PTEN mutation/variant-positive CS/CSL patients
were also found to have germline SDHx variants, and the
presence of SDHx variants appear to further modify PTEN mu-
tation cancer risks over those of PTEN mutation in isolation.
Because this is the ﬁrst observation of SDHx variation modi-
fying PTEN-related breast cancer risk, this will need to be
independently validated before translation into the routine
clinical armamentarium.
Among all 11 different SDHx variants we detected, there are
4 novel variants not previously reported in either NCBI SNP
Figure 3. p53 expression at both the protein and mRNA level. (A) Western blot of p53 protein in SDHx variant-positive CS/CSL (patient ID—SDHx variant:
829LL-S163P, 1965ML-S163P, 2094GR-H50R, 2549MP-G12S, 2854PS-S163P, 2894KP-H50R) and normal control groups. Upper panel shows the protein
proﬁle under normal culture condition, and lower panel after cells treated with 4 mM proteasomal inhibitor MG132 for 4 h. Tubulin served as a loading
control in both conditions. (B) Relative levels of p53 were quantitated by densitometry and normalized to tubulin. Results are fold change compared with
normal control cells, with (upper panel) or without MG132 treatment (lower panel). Data were presented as (mean + SEM). ∗P , 0.05. (C) Relative TP53
mRNA expression by quantitative RT–PCR in SDHx variant-positive samples compared with normal controls, with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as internal control. (D) Immunoprecipitation of p53 from control and SDH
var+ LCL whole-cell lysate blotting for NQO1 and p53, ∗indicates the light
chain band of IgG.
Human Molecular Genetics, 2012, Vol. 21, No. 2 305database (http://www.ncbi.nlm.nih.gov/snp/) or SDHx muta-
tion database (http://chromium.liacs.nl/lovd_sdh), SDHB
Arg27Gly, Asn120Ser, Ala215Thr and SDHC Ala66Val.
SDHC Ala66Val detected represents the ﬁrst SDHC variant
in a CSL patient, a 54-year-old patient with invasive breast
cancer, follicular thyroid cancer, uterine ﬁbroids and skin
hemangioma. Patients with SDHB Arg27Gly, Asn120Ser or
Ala215Thr variants all presented with invasive breast carcin-
oma and either malignant (papillary thyroid cancer) or
benign thyroid lesions. The other patient with SDHD
His145Asn (rs121908984) variant ﬁrst reported in our previ-
ous pilot study presented with both breast carcinoma and
RCC. The fact that carriers of these variants all presented
with malignant breast carcinoma suggest physiologic rele-
vance. SDHB Ala3Gly (rs11203289) and His57Arg
(rs35962811) were reported in dbSNP but only in African
American population, while our samples are derived from
white individuals of European ancestry. The most frequent
variants SDHB Ser163Pro (rs33927012), SDHD Gly12Ser
(rs34677591) and SDHD His50Arg (rs11214077) we seen in
our CS/CSL individuals have also been reported in the data-
base. Although these relatively common (1–5% frequency)
variants were computationally predicted to be functionally
benign (22), our experimental data provide molecular evi-
dence that they could have functional impact in cellular signal-
ing regulation as well. The reason why bioinformatic analysis
of prediction fails in SDHx genes is because they are extreme-
ly well conserved throughout species (23). With enormous
numbers of variations uncovered by whole genome sequen-
cing, it is essential to realize that functional analysis and clin-
ical correlations must be performed to deﬁne the true
pathogenic effect of DNA variations (24), as we have done
in the current study.
Changes in the mitochondrial metabolism have long been
linked to cancer, known as the Warburg effect (25). The
mechanism(s) of disruption of mitochondrial function
leading to neoplasia remain unclear. Succinate, the substrate
of SDH, may function as a second messenger between the
mitochondria (energy production body) and cytosol.
Accumulation of succinate due to SDHx mutations inhibit
Figure 4. Altered FAD/NAD levels in cells linked to p53 downregulation. (A) Nomalized FAD, NAD, NADH measurements in control and SDH
var+ cells. (B)
Normalized FAD, NAD, NADH measurements in four control cell lines with or without 250 mM FAD treatment for 48 h. (C) Two control cell lines were treated
with either 100 or 250 mM FAD for 48 h. Whole-cell lysate then was blotted for p53, PTEN, p-AKT, p-MAPK and GAPDH as loading control.
306 Human Molecular Genetics, 2012, Vol. 21, No. 2the prolyl-hydroxylase enzyme and contributes to stabilization
of HIF1a in turn promoting transcription of genes containing
hypoxic response elements believed to promote cancer (16).
Our data suggest that the hyperactivation of the HIF
pathway is indeed involved in our CS/CSL development. It
has been reported that the HIF signaling pathway can also
be regulated by AKT and mTOR signaling downstream of
PTEN (26). It is notable that HIF1a expression in PTEN
mutation-positive samples versus SDHx variant-only samples
are different. We observed no obvious accumulation of
HIF1a protein with PTEN mutation, consistent with other
reports that loss of function of PTEN most likely increases
the HIF1a transactivation function by preventing HIF1a
binding to HIF inhibitory factor (FIH), instead of stabilizing
HIF1a protein expression (27). This contrasts with our obser-
vation of SDHx-related hyperactivation of HIF1a. This differ-
ential involvement of HIF signaling may partially explain the
different levels of predisposition to breast, thyroid and/or renal
carcinomas in PTEN mutation positive or SDHx variant
positive, versus both.
As ‘energy factories’ through oxidative phosphorylation,
mitochondria make endogenous ROS as byproducts of
normal respiration. Under normal physiological conditions,
complex II is not considered to be a site for ROS generation.
However, the structure–function studies of bacterial Sdh and
fumarate dehydrogenase indicated ROS production mainly
resides at the FAD site of these enzymes (28). The succinate-
driven reverse-electron transfer through complex I was shown
as another mechanism to yield the highest rates of H2O2 in iso-
lated mitochondria (29). Therefore, accumulated succinate
from dysfunctional SDH complex not only could serve as a
second messenger activating HIF signaling (as discussed
above), but also could drive the intracellular ROS generation.
The extra ROS stress has been reported with SDHx mutations
(30), and also observed in our SDHx variant carrier cells in
general. Certain PTEN mutation-positive cells do show
elevated ROS (31), which accounts for the additive increased
ROS in samples with both PTEN mutation and SDHx variant.
Excessive oxidation of DNA by ROS could be a major cause
of DNA damage and genetic instability (32,33), which leads to
accumulation of mutations and deletions that eventually
contribute to carcinogenesis.
TP53, as a stress-induced tumor suppressor gene, plays
important roles in programmed cell death (34). The reduction
in basal p53 levels in SDHx variant carriers likely explains the
corresponding escape of cell death, which otherwise should be
regulated by the p53 pathway under normal cellular responses.
A recent study also suggested that mitochondrial respiration
deﬁciency may impair p53 expression and function (35),
which is consistent with our observation. We further investi-
gated the underlying mechanism of this p53 impairment
caused by SDHx variation. The tightly regulated p53 protein
levels are achieved via both ubiquitin-mediated degradation
in 26S proteasomes based on interactions between p53 and
Mdm2 (36), and an ubiquitin-independent degradation in
20S proteasomes (18–20,37). In the latter, p53 is degraded
by 20S proteasomes through direct binding to NQO1. What
is intriguing to us is that the function of NQO1 is tightly regu-
lated by mitochondrial redox metabolites. As a key player
here, NQO1 is a FAD-containing protein and its activity is
highly dependent on intracellular NAD
+/NADH, also the
product and substrate, respectively, of mitochondrial
complex I (38). Our data suggest that in our SDHx variant
cells, it is not the loss of absolute NQO1 expression but
Figure 5. Proposed signaling model of CS/CSL tumorigenesis caused by SDHx variants.
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that results in the reduction in p53 protein. The observation
that increased FAD and lowered NAD+ concentrations in
SDHx variant cells validates the observation of inhibited
NQO1 function. Presence of excessive FAD results in
activated signaling down the AKT and MAPK pathways,
mimicking PTEN dysfunction. Therefore, our ﬁndings reveal
a novel mechanism that mitochondrial metabolites regulate
cellular signaling, hence mechanistically linking mitochon-
drial dysfunction to tumorigenesis.
In conclusion, our genetic analyses revealed that germline
SDHx variants are associated with elevated cancer risks in
CS/CSL individuals, both alone and synergistically with germ-
line PTEN mutations. Our functional data suggest that disrup-
tion of complex II could lead to mitochondrial metabolite
imbalance, and in turn cause the stabilization of HIF1a, loss
of baseline p53 levels and is at least partially responsible for
ROS generation. The cross-talk between SDH and PTEN
results in a multi-signaling cascade that contributes to tumori-
genesis (Fig. 5). As we are learning more about the heterogen-
eity of tumor formation, it is not surprising to observe multiple
pathways crosstalk, contribute alone or simultaneously to the
ﬁnal outcome of differential organ-speciﬁc carcinogenesis.
Together, our ﬁndings suggest the importance of considering
SDHx as candidate predisposing genes and as candidate modi-
ﬁer genes for CS/CSL-related malignancy risks, and may also
guide future tailored preventative or therapeutic approaches.
MATERIALS AND METHODS
Subjects and germline DNA extraction
CS or CSL patients were prospectively enrolled in accordance
with our research protocol IRB8458-PTEN, which was
approved by the Cleveland Clinic and respective Institutional
Review Boards for Human Subjects Protection. All research
participants provided written informed consent. To be enrolled
in the IRB8458-PTEN, individuals are eligible if he/she meets
the full CS diagnostic criteria established by the International
Cowden Consortium (Supplementary Material, Table S1) or
the relaxed criteria (criteria minus one) according to version
2006 NCCN Guidelines (39). Patients meeting the relaxed
criteria are referred to as individuals with CSL phenotypes
or CSL. In other words, CSL was diagnosed when an individ-
ual did not fully meet the strict diagnostic criteria but had
features with one or two criteria short of the operational diag-
nostic criteria. Matching the subjects, normal (population)
controls are from northern and western European origin and
were anonymized prior to storage and analysis.
Germline DNA was extracted from peripheral blood
samples from patients and healthy controls by the Genomic
Medicine Biorepository (GMB), Genomic Medicine Institute,
Cleveland Clinic (protocols are available at GMB website,
http://www.lerner.ccf.org/gmi/gmb/methods.php).
Lightscanner and sequencing for mutation scanning
Genomic DNA was ﬁrst analyzed using high-resolution
melting LightScanner technology (Idaho Technology Inc.,
Salt Lake City, UT, USA), which detects nucleic acid
sequence variations, by changes in the melting curve.
Primers to amplify a total of 20 amplicons spanning the
exons, exon–intron junctions and ﬂanking intronic regions
as well as promoters of SDHB/C/D were designed using Light-
Scanner Primer Design software (all primers are listed in Sup-
plementary Material, Table S3) and optimized according to the
manufacturer’s instructions. Germline genomic DNA samples
were ampliﬁed with LCGreen
w Plus (Idaho Technology) in a
ﬁnal reaction volume of 10 ml with 20 ml oil overlay. The tem-
perature cycling protocol consisted of an initial denaturation
step at 958C for 2 min, followed by 37 cycles of denaturation
at 948C for 30 s, optimal annealing temperature for each
amplicon for 30 s and heteroduplex formation step at 958C
for 30 s and ﬁnal hold at 258C. Melting curve analysis was
performed on LightScanner with LightScanner software
employing three steps, namely, normalization, temperature
shift and generating difference plot to cluster samples.
Samples with melting curves that clustered differently from
reference samples were directly sequenced for SDHB, SDHC
or SDHD, as previously reported by our laboratory (40,41).
Cell lines and cell cultures
Human immortalized lyphoblastoid cell lines (LCLs) derived
from patients and controls were generated by Genomic Medi-
cine Biorepository, Genomic Medicine Institute, Cleveland
Clinic (protocols are available at GMB website, http://www.
lerner.ccf.org/gmi/gmb/methods.php). LCLs were cultured in
RPMI 1640 supplemented with 20% FBS and 100 units/ml
each of penicillin and streptomycin. All cell lines were cul-
tured at 378C with 5% CO2. NQO1 inducer DMF
(Sigma-Aldrich Co., St Louis, MO, USA) was added into
cell culture at different doses as described in ﬁgure legend.
RNA extraction and quantitative reverse-transcription–
PCR
TotalRNAwasextracted fromLCLsfromcontrolsandpatients
using RNeasy
w Mini Kit (QIAGEN, Inc., Valencia, CA, USA)
according to the manufacturer’s protocol, and subsequently
treated with DNase I (Invitrogen, Carlsbad, CA, USA). DNase-
treated total RNA from each LCL was reverse-transcribed into
cDNA using random primers and SuperTranscriptTM III
Reverse Transcriptase (Invitrogen), as speciﬁed by the manu-
facturer. PCR was performed using SYBR Green PCR Master
Mixandrunon7500RealTimePCRmachine(AppliedBiosys-
tem, Carlsbad, CA, USA) using the following intron-spanning
primers: 5′-GAAAAAGATAAGTTCTGAACGTCGAA-3′
and 5′-CCTTATCAAGATGCGAACTCACA-3′ for HIF1A;
5′-CTACCTCCACCATGCCAAGTG-3′ and 5′-TGATTCTG
CCCTCCTCCTTCT-3′ for VEGF; 5′-CTGTCCCTTCCCAG
AAAACCT-3′ and 5′-GGGAGTACGTGCAAGTCACAGA-
3′ for P53; 5′-GGGCTGCTTTTAACTCTGGTAA-3′ and 5′-A
TGGGTGGAATCATATTGGAAC-3′ for GAPDH.
Protein analysis
Whole-cell lysates were prepared as described before (42)
with M-PER Mammalian Protein Extraction Reagent (Ther-
moFisher Scientiﬁc, Waltham, MA, USA) supplemented
308 Human Molecular Genetics, 2012, Vol. 21, No. 2with protease inhibitor cocktail and phosphatase inhibitor
cocktail (Sigma-Aldrich). Lysates were either separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
and transferred to nitrocellulose or applied to nitrocellulose
with a dot blot apparatus (BioRad, Hercules, CA, USA). The
resulting blots were subjected to western blot analysis for
PTEN (6H2.1, Cascade Bioscience, Portland, OR, USA),
MnSOD (Upstate Biotechnology, Waltham, MA, USA),
HIF1a (BD Biosciences, San Jose, CA, USA), p53, Actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
a-tubulin (Sigma-Aldrich) protein levels.
ROS measurement
The measurement of ROS was performed using carboxy-
dichlorodihydroﬂuorescein diacetate (Carboxy-H2DCFDA), a
reliable ﬂuorogenic marker for ROS in live cells (Molecular
Probes, Invitrogen). The cells were washed with HBSS/Ca/
Mg buffer, centrifuged, resuspended in HBSS/Ca/Mg and
incubated with 25 mM carboxy-H2DCFDA for 30 min at
378C. Hoechst 33342 was added at a ﬁnal concentration of
1 mM to the carboxy-H2DCFDA staining solution during the
last 5 min of the incubation. Fluorescence imaging was
taken immediately after washing and mounting the samples.
For ﬂow cytometry measurement, cells were washed and
resuspended in HBSS/Ca/Mg buffer after incubation and
count with FACScans (Becton-Dickinson) immediately.
Cell cycle analysis by FACS ﬂow cytometry
LCLs were serum starved overnight and allowed to grow
under 0.2% FBS condition for 36 h before 70% ethanol ﬁx-
ation for cell cycle analysis using FACScan ﬂow cytometer
(Becton-Dickinson).
FAD, NAD1/NADH quantiﬁcation
FAD concentration was measured using FAD assay kit
#357-100 (BioVision, Mountain View, CA, USA) following
product protocol. In brief, cells were homogenized and depro-
teinized. Samples and FAD standard were incubated with FAD
enzyme mix, OxiRed Probe and assay buffer for 15–60 min
in duplicates before measured by the colorimetric method
(l ¼ 570 nm).
NAD and NADH concentrations were measured using
NAD+/NADH quantiﬁcation kit #337-100 (BioVision)
following product protocol. In brief, cells were extracted by
freeze/thaw two cycles (20 min on dry ice, then 10 min at
room temperature). Extracted samples were ﬁltered through
10 kDa molecular weight cut off ﬁlters (BioVison #1997-25)
to remove enzymes consuming NADH before performing
the assay. To detect total NADt (NADH and NAD), the
samples and NADH standard were incubated directly with
NAD cycling mix (cycling buffer and enzyme mix). To
detect NADH, samples were heated to 608C for 30 min to
decompose NAD before incubating with NAD cycling mix.
Duplicated samples were then mixed with NADH developer
and incubated at room temperature for 1–4 h before colori-
metric reading at OD 450 nm. The amount of NAD in
samples was calculated by subtracting NADH from NADt.
Statistical analysis
The frequency of each of the carcinomas in SDHx variant-
positive individuals were compared with that in a cohort of
105 PTEN mutation-positive individuals with the CS/CSL
phenotype. Fisher’s two-tailed exact test was applied with
the signiﬁcance at P , 0.05.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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